The psychotic symptoms, delusions and hallucinations, are present in at least 30-40% of patients with Alzheimer's disease (AD). Psychotic symptoms in AD patients (AD+P) predict more rapid functional decline and premature institutionalization. Current treatments for AD+P are inadequate. We have hypothesized a polygenic model of AD+P. In preliminary tests of this hypothesis of this hypothesis, we have found that AD+P was significantly more frequent in patients with specific genotypes at the dopamine1 (D1) and D3 receptor loci (Sweet et a., 1998). Similarly, Holmes et al. (1998) reported an association in AD patients with variation in the serotonin/2A (5-HT2A) and 5-HT2C receptor genes. We propose to establish a cohort of 644 subjects, prospectively and longitudinally characterized with regard to psychosis phenotype, for examination of the genetic determinants of AD+P. Subjects with mild cognitive impairment, possible AD and probable AD will be evaluated at presentation to the Alzheimer's Disease Research Centers of the University of Pittsburgh and the University of Pennsylvania. Genetic material will be obtained. Neuropsychiatric assessments of psychotic symptoms will be conducted, with ratings on the CERAD Behavioral Rating Scale. Subjects without current or prior psychotic symptoms will be followed longitudinally with repeat assessments for psychotic symptoms every 6 months. Telephone assessments will be used for subjects unable to return to minimize incomplete data due to drop-outs. We project 20%-30% of the 644 subjects without psychosis at baseline will develop incident AD+P during the study interval. We hypothesize: 1) D1 receptor genotype will predict onset of AD+P; 2) D3 receptor genotype will predict onset of AD+P; 3) 5-HT2A receptor genotype will predict onset of visual hallucinations; 4) H-HT2C receptor genotype will predict onset of visual hallucinations. This study would be the first to prospectively evaluate the contribution of specific genes to predicting the onset of psychotic symptoms in any disorder. Replicated findings would provide a compelling rationale for family-based studies to address population stratification effects and for pursuit of the identified receptors as targets for drug development. Finally, establishing an AD cohort with prospectively determined psychosis phenotype will facilitate the research for novel risk genes as new genetic technologies become available.
| Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555 |
| Brainstorm Consortium (see original citation for additional authors) (2018) Analysis of shared heritability in common disorders of the brain. Science 360: |
| Koch, Manja; DeKosky, Steven T; Fitzpatrick, Annette L et al. (2018) Apolipoproteins and Alzheimer's pathophysiology. Alzheimers Dement (Amst) 10:545-553 |
| Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487 |
| Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104 |
| Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry : |
| Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325 |
| Baskota, Swikrity Upadhyay; Lopez, Oscar L; Greenamyre, J Timothy et al. (2018) Spectrum of tau pathologies in Huntington's disease. Lab Invest : |
| Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826 |
| Lopez, Oscar L; Becker, James T; Chang, YueFang et al. (2018) Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology 90:e1920-e1928 |
Showing the most recent 10 out of 667 publications
